Grace Therapeutics (FRA:L8S) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:L8S Grace Therapeutics Inc FRA:L8S
33 GF Score
Price €2.78
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Grace Therapeutics  (FRA:L8S) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Grace Therapeutics Cyclically Adjusted PB Ratio Related Terms


Grace Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics Cyclically Adjusted PB Ratio Chart

Grace Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Grace Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:L8S vs VERU, TVGN, MGX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Grace Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grace Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:L8S
33GF Score
Grace Therapeutics Inc FRA:L8S
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Grace Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Grace Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.591/333.9520*333.9520
=2.591

Current CPI (Jun. 2026) = 333.9520.

Grace Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201602 82.870 237.111 116.716
201605 74.252 240.229 103.221
201608 67.496 240.849 93.587
201611 62.107 241.353 85.935
201706 41.802 244.955 56.989
201709 32.619 246.819 44.134
201712 19.566 246.524 26.505
201803 9.711 249.554 12.995
201806 6.433 251.989 8.525
201809 -12.921 252.439 -17.093
201812 12.050 251.233 16.017
201903 5.718 254.202 7.512
201906 1.455 256.143 1.897
201909 -0.652 256.759 -0.848
201912 -2.288 256.974 -2.973
202006 5.100 257.797 6.607
202009 3.749 260.280 4.810
202012 6.464 260.474 8.287
202103 10.909 264.877 13.754
202106 10.384 271.696 12.763
202109 13.350 274.310 16.253
202112 13.231 278.802 15.848
202203 13.183 287.504 15.313
202206 13.467 296.311 15.178
202209 13.751 296.808 15.472
202212 12.188 296.797 13.714
202303 8.412 301.836 9.307
202306 7.890 305.109 8.636
202309 6.707 307.789 7.277
202312 6.229 306.746 6.781
202403 6.082 312.332 6.503
202406 5.463 314.175 5.807
202409 4.960 315.301 5.253
202412 4.966 315.605 5.255
202503 4.495 319.799 4.694
202506 3.915 322.561 4.053
202509 3.784 324.800 3.891
202512 3.571 324.054 3.680
202603 3.461 330.213 3.500
202606 2.591 333.952 2.591

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Grace Therapeutics Business Description

Other Exchanges GRCE:USA
Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
33GF Score

Get the complete analysis for FRA:L8S

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.78
Price